tiprankstipranks
Trending News
More News >

Ovid Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Ovid Therapeutics (OVID) to $1.50 from $2 and keeps a Buy rating on the shares. Ovid currently trades at a negative enterprise value and remains slated to deliver multiple potential value inflection points over the next 12 months, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue